Experiment 1218642
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | ECKHARDT,S: HERNADI,Z: THURZO,L: TELEKES,A: SOPKOVA,B: MECHL,Z: PAWLICKI,M: KERPEL-FRONIUS,S:. (1990). PHASE II CLINICAL EVALUATION OF ETOPOSIDE (VP-16-213, VEPESID) AS A SECOND-LINE TREATMENT IN OVARIAN CANCER.. 47(4) |
| Amount utilized | |
| Compound isolated | |
| Disease | 71 PATIENTS WITH OVARIAN CANCER WERE TREATED IN A PHASE 2 TRIAL. THE OVERALL RESPONSE RATE WAS 8.4%. 1 PATIENT ACHIEVED COMPLETE REMISSION AND 5 ACHIEVED PARTIAL REMISSION. IN 48 PATIENTS, MINOR REMISSION OR STABLE DISEASE WAS ACHIEVED. COMMON SIDE EFFECTS INCLUDED ALOPECIA, NAUSEA AND VOMITING. |
| Dose amount | VAR |
| Number | 1 |
| Qualitative result | . |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |